利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

1636 条记录 (耗时 0.021 秒)

    COMPOSITIONS FOR TREATING RESPIRATORY VIRAL INFECTIONS AND THEIR USE
    92.
    发明申请
    COMPOSITIONS FOR TREATING RESPIRATORY VIRAL INFECTIONS AND THEIR USE 审中-公开
    用于治疗呼吸道病毒感染的组合物及其使用

    公开(公告)号：WO2006121464A3

    公开(公告)日：2007-06-28

    申请号：PCT/US2005040048

    申请日：2005-11-04

    申请人： INTRADIGM CORP ,  TANG QINGQUAN ,  LU PATRICK Y ,  XIE FRANK Y ,  WOODLE MARTIN C ,  ZHENG BOJIAN

    发明人： TANG QINGQUAN ,  LU PATRICK Y ,  XIE FRANK Y ,  WOODLE MARTIN C ,  ZHENG BOJIAN

    IPC分类号： A61K48/00 ,  C07K14/11 ,  C07K14/135 ,  C12N15/113

    CPC分类号： A61K31/711 ,  A61K31/7105 ,  C12N15/1131 ,  C12N2310/111 ,  C12N2310/14 ,  C12N2310/53 ,  C12N2760/16111 ,  C12N2760/18511

    摘要： The invention provides siRNA compositions that interfere with viral replication in respiratory viral infections, including respiratory syncytial virus and avian influenza A, including the H5N1 strain. The invention further provides uses of the siRNA compositions to inhibit expression of viral genes in respiratory virus-infected cells, and to uses in the treatment of respiratory virus infections in a subject. Generally the invention provides polynucleotide that includes a first nucleotide sequence of 15 to 30 bases that targets the genome of a respiratory syncytial virus or an influenza A virus, a complement thereof, a double stranded polynucleotide or a hairpin polynucleotide. Additionally the invention provides vectors, cells and pharmaceutical compositions containing siRNA sequences.

    摘要翻译： 本发明提供干扰呼吸道病毒感染（包括呼吸道合胞病毒和禽流感A）包括H5N1毒株在内的病毒复制的siRNA组合物。 本发明还提供siRNA组合物用于抑制呼吸道病毒感染细胞中病毒基因表达的用途，以及用于治疗受试者中的呼吸道病毒感染的用途。 本发明通常提供多核苷酸，其包含15至30个碱基的第一核苷酸序列，其靶向呼吸道合胞病毒或甲型流感病毒的基因组，其补体，双链多核苷酸或发夹多核苷酸。 另外，本发明提供了含有siRNA序列的载体，细胞和药物组合物。

    INHIBITION OF PAX2 BY DEFB1 INDUCTION AS A THERAPY FOR CANCER
    94.
    发明申请
    INHIBITION OF PAX2 BY DEFB1 INDUCTION AS A THERAPY FOR CANCER 审中-公开
    通过DEFB1诱导作为治疗癌症的PAX2的抑制作用

    公开(公告)号：WO2007047512A3

    公开(公告)日：2007-06-14

    申请号：PCT/US2006040215

    申请日：2006-10-16

    申请人： MUSC FOUND FOR RES DEV ,  DONALD CARLTON D

    发明人： DONALD CARLTON D

    IPC分类号： C12N5/00 ,  A01N43/04 ,  A61K31/70 ,  C07H21/04 ,  C12N5/02

    CPC分类号： C12N15/115 ,  C07K14/4723 ,  C12N15/113 ,  C12N2310/111 ,  C12N2310/14

    摘要： Provided is a method of treating cancer in a subject by inhibiting expression of PAX2. An example of a cancer treated by the present method is prostate cancer. Similarly, provided is a method of treating cancer in a subject by increasing expression of DEFBl in the subject. In the method wherein the expression of DEFBl is increased, it can be increased by blocking the binding of PAX2 to the DEFBl promoter. Blocking the binding of PAX2 to the DEFBl promoter can be by administration of an oligonucleotide containing the PAX2 DNA binding site of DEFBl. This oligonucleotide can be complementary to the sequence of PAX2 that binds to the DEFBl promoter. Alternatively, the oligonucleotide can interact with the PAX2 in a way that inhibits binding to DEFBl.

    摘要翻译： 提供了通过抑制PAX2的表达来治疗受试者的癌症的方法。 通过本方法治疗的癌症的实例是前列腺癌。 类似地，提供了通过增加受试者中DEFB1的表达来治疗受试者的癌症的方法。 在DEFB1的表达增加的方法中，可以通过阻断PAX2与DEFB1启动子的结合而增加。 阻断PAX2与DEFB1启动子的结合可以是通过施用含有DEFB1的PAX2 DNA结合位点的寡核苷酸。 该寡核苷酸可以与结合DEFB1启动子的PAX2的序列互补。 或者，寡核苷酸可以以抑制与DEFB1结合的方式与PAX2相互作用。

    TARGETING PAX2 FOR THE INDUCTION OF DEFB1-MEDIATED TUMOR IMMUNITY AND CANCER THERAPY
    98.
    发明申请
    TARGETING PAX2 FOR THE INDUCTION OF DEFB1-MEDIATED TUMOR IMMUNITY AND CANCER THERAPY 审中-公开
    引导PAX2诱导DEFB1介导的肿瘤免疫和癌症治疗

    公开(公告)号：WO2007047512A2

    公开(公告)日：2007-04-26

    申请号：PCT/US2006/040215

    申请日：2006-10-16

    申请人： MUSC FOUNDATION FOR RESEARCH DEVELOPMENT ,  DONALD, Carlton, D.

    发明人： DONALD, Carlton, D.

    IPC分类号： A61K48/00

    CPC分类号： C12N15/115 ,  C07K14/4723 ,  C12N15/113 ,  C12N2310/111 ,  C12N2310/14

    摘要： Provided is a method of treating cancer in a subject by inhibiting expression of PAX2. An example of a cancer treated by the present method is prostate cancer. In the cancer treatment methods disclosed, the method of inhibiting expression of PAX 2 can be by administration of a nucleic acid encoding an siRNA for PAX 2. Dharmachon is a commercial source for such siRNAs. A method of treating cancer in a subject by administering DEFBl is also provided. An example of a cancer treated by the present method is prostate cancer. Similarly, provided is a method of treating cancer in a subject by increasing expression of DEFBl in the subject. In the method wherein the expression of DEFBl is increased, it can be increased by blocking the binding of PAX2 to the DEFBl promoter. The blocking of binding of PAX2 to the DEFBl promoter can be by administration of an oligonucleotide containing the PAX2 DNA binding site of DEFBl. This oligonucleotide can be complementary to the sequence of PAX2 that binds to the DEFBl promoter. Alternatively, the oligonucleotide can interact with the PAX2 in a way that inhibits binding to DEFBl. This interaction can be based on three-dimensional structure rather than primary nucleotide sequence.

    摘要翻译： 提供了通过抑制PAX2的表达来治疗受试者的癌症的方法。 通过本方法治疗的癌症的实例是前列腺癌。 在所公开的癌症治疗方法中，抑制PAX2表达的方法可以是通过施用编码PAX2的siRNA的核酸.Dharmachon是这样的siRNA的商业来源。 还提供了通过施用DEFB1治疗受试者的癌症的方法。 通过本方法治疗的癌症的实例是前列腺癌。 类似地，提供了通过增加受试者中DEFB1的表达来治疗受试者的癌症的方法。 在DEFB1的表达增加的方法中，可以通过阻断PAX2与DEFB1启动子的结合而增加。 阻断PAX2与DEFB1启动子的结合可以是通过施用含有DEFB1的PAX2 DNA结合位点的寡核苷酸。 该寡核苷酸可以与结合DEFB1启动子的PAX2的序列互补。 或者，寡核苷酸可以以抑制与DEFB1结合的方式与PAX2相互作用。 这种相互作用可以基于三维结构而不是一级核苷酸序列。

    INHIBITION OF SPAG9 EXPRESSION WITH SIRNAS
    99.
    发明申请
    INHIBITION OF SPAG9 EXPRESSION WITH SIRNAS 审中-公开
    用SIRNAS抑制SPAG9表达

    公开(公告)号：WO2006092714A3

    公开(公告)日：2007-03-15

    申请号：PCT/IB2006000445

    申请日：2006-03-02

    申请人： NAT INST IMMUNOLOGY ,  SURI ANIL KUMAR

    发明人： SURI ANIL KUMAR

    IPC分类号： C12N15/113

    CPC分类号： C12N15/113 ,  C12N2310/111 ,  C12N2310/14

    摘要： The present invention relates to the field of cancer therapy. More specifically, the invention relates to use of small interfering RNAs targeting the SPAG9 (CAA62987) gene for the treatment of cancer.

    摘要翻译： 本发明涉及癌症治疗领域。 更具体地，本发明涉及靶向SPAG9（CAA62987）基因的小干扰RNA用于治疗癌症的用途。